Manokar Panchanatham has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Calcium-Modification Techniques in Calcified Coronary Artery Disease: A Systematic Review of Comparative Evidence on Procedural Success, Complications and Clinical Outcomes

    by Sundar Chidambaram, Manokar Panchanatham, Mahadevan Venkataramani, Maheshbabu Panchanatham, Jebaraj Rathinasamy, Deepchand Raja, Nithesh Kumar, Surendar Gunasekaran, Selva Prakash, Nagendra Boopathy Senguttuvan, et al.

    Background/Objectives: Severe coronary calcification complicates percutaneous coronary intervention (PCI), and several calcium-modification technologies are available, but direct randomized comparisons are limited. We reviewed the comparative evidence on procedural success, complications and clinical outcomes. Methods: Comparative studies of coronary calcium-modification techniques during PCI that reported procedural, safety or clinical outcomes were eligible. PubMed and ClinicalTrials.gov were searched in May 2025 for records published from 1 April 2015 to 1 April 2025 (PROSPERO CRD420251077471; no external funding). We included 32 publications: eight randomized trials (10 publications) and 22 observational or descriptive studies. Evidence was organized in tiers and synthesized descriptively, without pooling, because definitions were heterogeneous and event rates were low. Risk of bias in randomized trials was assessed with RoB 2 where full texts were accessible. Results: Procedural success was generally high (usually 85–100%) and major complications were uncommon, but success definitions differed, and reported dissection (0% to over 80%) and slow-flow (0% to 31.6%) rates varied widely. Most comparative data were observational. In randomized comparisons, no device consistently outperformed another for procedural success, stent expansion or minimal stent area. Clinical outcome comparisons were limited by heterogeneous endpoints and low event rates. Risk of bias was rated from full texts for five out of the eight randomized trials, none at low risk overall; ratings for the others were provisional or not possible. Conclusions: The evidence is largely observational and of low certainty, and is insufficient to establish clinically meaningful differences among most technologies. Device selection should be lesion-specific and imaging-informed, and adequately powered head-to-head trials with standardized endpoints are needed.

  • TCTAP C-033 CHIP - Choice OR Only Option..!! For Complicated Post Covid Case With Severely Calcified LM Trifurcation Lesion

    by Harsimran Singh, Nagendra Boopathy Senguttuvan, Ramesh Sankaran, Vinod Kumar Balakrishnan, S. Sadhanandham, Venkata Balasubramaniyan Jayanty, Preetam Krishnamurthy, Manokar Panchanatham, Thoddi Ramamurthy Muralidharan

  • Open Access

    Clinical profile and management of patients with acute pulmonary thromboembolism – a single centre, large observational study from India

    by Thoddi Ramamurthy Muralidharan, Sankaran Ramesh, Balakrishnan Vinod Kumar, Aditya V. Ruia, Mohan Kumar, Akshaya Gopalakrishnan, Gurpreet S. Johal, Amit Hooda, Rohit Malhotra, Reza Masoomi, et al.

    Acute pulmonary thromboembolism is associated with high mortality, similar to that of myocardial infarction and stroke. We studied the clinical presentation and management of pulmonary thromboembolism in the Indian population. An analysis of 140 patients who presented with acute pulmonary thromboembolism at a large volume center in India from June 2015 through December 2018 was performed. The mean age of our study population was 50 years with 59% being male. Comorbidities including deep vein thrombosis, diabetes mellitus, hypertension, and chronic obstructive pulmonary disease were present in 52.9%, 40%, 35.7% and 7.14% of patients, respectively. Out of 140 patients, 40 (28.6%) patients had massive pulmonary thromboembolism, 36 (25.7%) sub‐massive pulmonary thromboembolism, and 64 (45.7%) had low‐risk pulmonary thromboembolism. Overall, in‐hospital mortality was 25.7%. Multivariate regression analysis found chronic kidney disease and pulmonary thromboembolism severity to be the only independent risk factors. Thrombolysis was performed in 62.5% of patients with a massive pulmonary thromboembolism and 63.9% of patients with a sub‐massive pulmonary thromboembolism. In the massive pulmonary thromboembolism group, patients receiving thrombolytic therapy had lower mortality compared with patients who did not receive therapy (p=0.022), whereas this difference was not observed in patients in the sub‐massive pulmonary thromboembolism group. We conclude that patients with acute pulmonary thromboembolism in India presented more than a decade earlier than our western counterparts, and it was associated with poor clinical outcomes. Thrombolysis was associated with significantly reduced in‐hospital mortality in patients with massive pulmonary thromboembolism.